Clinical Trial Update: Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP) [EARLY_Phase 1]

View source ↗

Summary

PRG-1801 is being evaluated for safety and efficacy in patients with recurrent or refractory primary immune thrombocytopenia, in an early-phase 1 trial that is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• PRG-1801

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Immune Thrombocytopenia | EARLY_Phase 1 | Status: RECRUITING